New combo therapy aims to control spread of nasopharyngeal cancer

NCT ID NCT04944914

First seen May 07, 2026 · Last updated May 15, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether adding stereotactic body radiotherapy (precise radiation) to the immunotherapy drug camrelizumab helps control cancer better than camrelizumab alone in people with nasopharyngeal carcinoma that has spread to a few spots (oligometastatic). The study includes 188 adults aged 18-70 whose primary tumor is controlled and who have had at least one round of chemotherapy. The main goal is to see how long the cancer stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.